Related references
Note: Only part of the references are listed.JAK/STAT inhibitors for the treatment of atopic dermatitis
Maria Alexandra Rodrigues et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2020)
Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the USA
L. Andersen et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata
Ji Su Lee et al.
JOURNAL OF DERMATOLOGY (2019)
Tofacitinib for the treatment of alopecia areata in preadolescent children
Brittany G. Craiglow et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Ruxolitinib for the treatment of severe alopecia areata
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Server Serdaroglu et al.
DERMATOLOGIC THERAPY (2019)
Eosinophil Count and Serum Immunoglobulin E Levels in Atopic Dermatitis: Analysis of Upadacitinib Phase 2 Study Findings
Lisa A. Beck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Ruxolitinib Cream Suppresses Th2 Inflammation in Adult Patients With Atopic Dermatitis
Sherry Owens et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
Erika L. Crowley et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2019)
The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature
Nicole Relke et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2019)
JAK inhibitors for alopecia areata: a systematic review and meta-analysis
K. Phan et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
What's New in Atopic Dermatitis
Yael Renert-Yuval et al.
DERMATOLOGIC CLINICS (2019)
998 Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients
S. Owens et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
1024 Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates
T. Song et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
E. Guttman-Yassky et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
Francisco Gomez-Garcia et al.
BMJ OPEN (2019)
New and Emerging Therapies for Pediatric Atopic Dermatitis
Henry L. Nguyen et al.
PEDIATRIC DRUGS (2019)
JAK Inhibitors for Atopic Dermatitis: An Update
Helen He et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2019)
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Nawaf Almutairi et al.
DERMATOLOGY (2019)
Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
Vivek S. Purohit et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Tofacitinib therapy for children with severe alopecia areata
Ying-Xiu Dai et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
S. C. Gordon et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)
Importance of light in the treatment of vitiligo with JAK-inhibitors
Deep Joshipura et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
H. Nakagawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
The multidimensional burden of psoriasis
P. Gisondi
BRITISH JOURNAL OF DERMATOLOGY (2018)
45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Zurich, Switzerland, March 7-10, 2018
EXPERIMENTAL DERMATOLOGY (2018)
Emerging drugs for alopecia areata: JAK inhibitors
Matilde Iorizzo et al.
EXPERT OPINION ON EMERGING DRUGS (2018)
A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient
Nupur U. Patel et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2018)
Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib
Ji Su Lee et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2018)
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
Hidemi Nakagawa et al.
JOURNAL OF DERMATOLOGY (2018)
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
A. Jabbari et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Effects of the oral janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD)
E. Simpson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD)
M. Gooderham et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
A. Bitterman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
Elana Putterman et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
Deep Joshipura et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Topical Janus kinase inhibitors: A review of applications in dermatology
Anna-Marie Hosking et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose. Narrowband UV-B Phototherapy
Sa Rang Kim et al.
JAMA DERMATOLOGY (2018)
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Andrea C. Tricco et al.
ANNALS OF INTERNAL MEDICINE (2018)
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study
Laita Bokhari et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
JAK Inhibitors for Treatment of Alopecia Areata
Eddy H. C. Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases
Jared Kahn et al.
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY (2018)
Role of janus kinase inhibitors in the treatment of alopecia areata
Korn Triyangkulsri et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
UPADACITINIB EFFECT ON PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS; FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
L. Beck et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2018)
Alopecia Universalis and Chronic Graft-vs-Host Disease Treated With Ruxolitinib
Michelle A. Borg et al.
JAMA DERMATOLOGY (2018)
Factors influencing cardiometabolic risk profile in patients with psoriasis
Neus Curco et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2018)
Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient
Yuval Ramot et al.
SKIN APPENDAGE DISORDERS (2018)
Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Amy Vandiver et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2017)
A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata
Maya Deeb et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2017)
Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
Aniseh Samadi et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2017)
An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
A. Jabbari et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review
O. Ibrahim et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series
Hyun-Sun Park et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
Leslie Castelo-Soccio
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata
Cheryl B. Bayart et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
JAK inhibitors in dermatology: The promise of a new drug class
William Damsky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Janus kinase inhibitors in dermatology: A systematic review
Rony Shreberk-Hassidim et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Brooke Rothstein et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
SUCCESSFUL HAIR REGROWTH IN A KOREAN PATIENT WITH ALOPECIA UNIVERSALIS FOLLOWING TOFACITINIB TREATMENT
Bo Young et al.
SINGAPORE MEDICAL JOURNAL (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
Beverley J. Shea et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Treatment of Alopecia Areata With Tofacitinib
Omer Ibrahim et al.
JAMA DERMATOLOGY (2017)
Brazilian Experience of the Treatment of Alopecia Universalis with the Novel Antirheumatic Therapy Tofacitinib: A Case Series
Morton Scheinberg et al.
RHEUMATOLOGY AND THERAPY (2017)
Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors
Katharina Welsch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Kresimir Kostovic et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Reversal of Alopecia Universalis by Tofacitinib: A Case Report
Morton Scheinberg et al.
ANNALS OF INTERNAL MEDICINE (2016)
Alopecia areata and health-related quality of life: a systematic review and meta-analysis
F. Rencz et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
R. Bissonnette et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
Ali Jabbari et al.
EXPERIMENTAL DERMATOLOGY (2016)
Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL)
Kosar Hedayat et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2016)
An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
A. Jabbari et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
John E. Harris et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Efficacy of tofacitinib in treatment of alopecia universalis in two patients
A. K. Gupta et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2016)
Tofacitinib Citrate for the Treatment of Nail Dystrophy AssociatedWith Alopecia Universalis
Arjun Dhayalan et al.
JAMA DERMATOLOGY (2016)
Topical Ruxolitinib for the Treatment of Alopecia Universalis
Brittany G. Craiglow et al.
JAMA DERMATOLOGY (2016)
Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Milene Kennedy Crispin et al.
JCI INSIGHT (2016)
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Julian Mackay-Wiggan et al.
JCI INSIGHT (2016)
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Florian Anzengruber et al.
CASE REPORTS IN DERMATOLOGY (2016)
Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
Sineida Berbert Ferreira et al.
CASE REPORTS IN DERMATOLOGY (2016)
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Lauren L. Levy et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Tofacitinib Citrate for the Treatment of Vitiligo A Pathogenesis-Directed Therapy
Brittany G. Craiglow et al.
JAMA DERMATOLOGY (2015)
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Ali Jabbari et al.
EBIOMEDICINE (2015)
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia
Lisa Pieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Scoping reviews: time for clarity in definition, methods, and reporting
Heather L. Colquhoun et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2014)
Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
Brittany G. Craiglow et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing et al.
NATURE MEDICINE (2014)
The many faces of Janus kinase
Matthew M. Seavey et al.
BIOCHEMICAL PHARMACOLOGY (2012)
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Alopecia in the United States: Outpatient utilization and common prescribing patterns
Amy J. McMichael et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
Share Paper
